ITULAZAX® tree pollen tablet approved for treatment of children in Europe

ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX^® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets.